Bristol Myers Squibb will present data at the 2024 Annual Meeting of the American Society of Clinical Psychopharmacology to be held May 28-31, 2024 in Miami, Florida.Research to be presented at the.
Consistent with short-term studies, KarXT was not associated with clinically meaningful changes in movement disorder scale scores and a low incidence rate of extrapyramidal symptoms was reported over.
Sotyktu maintains results, safety through 4 years of treatment for plaque psoriasis healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
Following four years of continuous Sotyktu treatment, clinical response was maintained in more than seven out of 10 patients for Psoriasis Area and Severity Index 75 in the POETYK PSO long-term.
Bristol Myers Squibb today announced new four-year results from the extension of a trial of Sotyktu in adult patients with moderate-to-severe plaque psoriasis. The data [.] continue to reinforce.